

# Kelly C Nelson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4809840/publications.pdf>

Version: 2024-02-01

54  
papers

1,611  
citations

361413

20  
h-index

345221

36  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1928  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
2	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
3	Role of different pathways of the complement cascade in experimental bullous pemphigoid. <i>Journal of Clinical Investigation</i> , 2006, 116, 2892-2900.	8.2	100
4	Basal Cell and Squamous Cell Skin Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 836-864.	4.9	98
5	Clinicopathologic study of 85 cases of melanoma of the female genitalia. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 598-605.	1.2	81
6	Merkel Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 322-332.	4.9	70
7	Prognostic Gene Expression Profiling in Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 1004.	4.1	59
8	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
9	Patients' Preferences for Biopsy Result Notification in an Era of Electronic Messaging Methods. <i>JAMA Dermatology</i> , 2015, 151, 513.	4.1	47
10	Addressing the Knowledge Gap in Clinical Recommendations for Management and Complete Excision of Clinically Atypical Nevus/Dysplastic Nevus. <i>JAMA Dermatology</i> , 2015, 151, 212.	4.1	43
11	Evaluation of the Number-Needed-to-Biopsy Metric for the Diagnosis of Cutaneous Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 1167.	4.1	42
12	Merkel Cell Carcinoma, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 410-424.	4.9	41
13	Reduction in nevus biopsies in patients monitored by total body photography. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 135-143.e5.	1.2	39
14	Dermatofibrosarcoma Protuberans. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 312-318.	4.9	38
15	Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 229-236.	1.2	38
16	Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 764-773.	1.3	38
17	Valdecoxib-associated acute generalized exanthematous pustulosis. <i>Burns</i> , 2005, 31, 383-387.	1.9	32
18	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	4.1	29

#	ARTICLE	IF	CITATIONS
19	Dermatofibrosarcoma Protuberans, Version 1.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 863-868.	4.9	28
20	Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society. Journal of the American Academy of Dermatology, 2019, 80, 1585-1593.	1.2	26
21	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. Journal of Cutaneous Pathology, 2018, 45, 504-507.	1.3	25
22	Standardized patient identification and specimen labeling: A retrospective analysis on improving patient safety. Journal of the American Academy of Dermatology, 2013, 68, 53-56.	1.2	20
23	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. Journal of Cutaneous Pathology, 2018, 45, 786-790.	1.3	18
24	Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. Journal of Cutaneous Pathology, 2018, 45, 539-544.	1.3	13
25	Evaluation of 39 cases of pediatric cutaneous head and neck melanoma. Journal of the American Academy of Dermatology, 2011, 65, e37-e42.	1.2	12
26	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer, 2022, 128, 975-983.	4.1	12
27	A systematic review and synthesis of qualitative and quantitative studies evaluating provider, patient, and health care system-related barriers to diagnostic skin cancer examinations. Archives of Dermatological Research, 2022, 314, 329-340.	1.9	11
28	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. International Journal of Dermatology, 2019, 58, 1045-1052.	1.0	11
29	Skin Cancer Education Interventions for Primary Care Providers: A Scoping Review. Journal of General Internal Medicine, 2022, 37, 2267-2279.	2.6	10
30	Pathologic Features of Pediatric Head and Neck Melanoma. Pediatric Dermatology, 2013, 30, 568-573.	0.9	8
31	Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. Journal of Cutaneous Pathology, 2020, 47, 954-959.	1.3	8
32	Melanoma-associated retinopathy: A presenting sign of metastatic disease. Journal of the American Academy of Dermatology, 2011, 65, e9-e11.	1.2	7
33	North, South, or East? Blotting Techniques. Journal of Investigative Dermatology, 2013, 133, 1-3.	0.7	7
34	Management strategies of academic pigmented lesion clinic directors in the United States. Journal of the American Academy of Dermatology, 2018, 79, 367-369.	1.2	7
35	Triple therapy with intralesional 5-fluorouracil, chemowraps, and acitretin: A well-tolerated option for treatment of widespread cutaneous squamous cell carcinomas on the legs. JAAD Case Reports, 2019, 5, 1051-1054.	0.8	7
36	Telementoring and smartphone-based answering systems to optimize dermatology resident dermoscopy education. Journal of the American Academy of Dermatology, 2019, 81, e27-e28.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 61-81.	1.3	5
38	Reflectance Confocal Microscopy Features of Angioma Serpiginosum. <i>Archives of Dermatology</i> , 2011, 147, 878.	1.4	4
39	Observation of Moderately Dysplastic Nevi With Positive Margins. <i>JAMA Dermatology</i> , 2018, 154, 1387.	4.1	4
40	Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 490-493.	1.3	4
41	Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 674-679.	1.3	4
42	Dermoscopy Proficiency Expectations for US Dermatology Resident Physicians. <i>JAMA Dermatology</i> , 2021, 157, 189.	4.1	4
43	Spreading Bumps: Molluscum Contagiosum in the Pediatric Population. <i>Pediatric Annals</i> , 2007, 36, 814-818.	0.8	4
44	Melanoma toolkit for early detection for primary care providers: A pilot study. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 984-986.	3.3	3
45	Have melanoma and skin cancer finally met their match?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 267-268.	27.6	2
46	Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 36-46.	1.3	2
47	Nanotechnology and the Diagnosis of Cutaneous Malignancies. , 2013, , 127-132.		1
48	Patient safety and quality care. <i>Clinics in Dermatology</i> , 2014, 32, 542-544.	1.6	1
49	A Pilot Educational Intervention to Support Primary Care Provider Performance of Skin Cancer Examinations. <i>Journal of Cancer Education</i> , 2023, 38, 364-369.	1.3	1
50	Educational Interventions to Support Primary Care Provider Performance of Diagnostic Skin Cancer Examinations: A Systematic Literature Review. <i>Journal of Cancer Education</i> , 2022, 37, 1579-1588.	1.3	1
51	Sensitivity and Specificity for Skin Cancer Diagnosis in Primary Care Providers: a Systematic Literature Review and Meta-analysis of Educational Interventions and Diagnostic Algorithms. <i>Journal of Cancer Education</i> , 2022, 37, 1563-1572.	1.3	1
52	The estimated financial impact of diagnostic accuracy on melanoma diagnosis in 2018.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18903-e18903.	1.6	0
53	Validation of a Novel Cutaneous Neoplasm Diagnostic Self-Efficacy Instrument (CNDSEI) for Evaluating User-Perceived Confidence With Dermoscopy. <i>Dermatology Practical and Conceptual</i> , 2020, 10, e2020088.	0.9	0
54	Persistent Facial and Chest Papular and Pustular Eruption in a Stem Cell Transplant Patient. <i>Transplantation Direct</i> , 2021, 7, e793.	1.6	0